More than 60% of all pharmaceutical target proteins and the majority of all new pharmaceuticals and vaccines, are protein-based. In research and development, and production of these protein-based therapeutics, finding the optimal conditions for protein production is often a time-consuming and laborious process. Xbrane Bioscience has two tightly-controlled bacterial protein expression systems. They enable expression of host-toxic and challenging proteins, as well as high yields of soluble proteins.
Xbrane Bioscience AB
Xbrane Bioscience aims to take protein production in E. coli to the next level. We enable our customers to produce their proteins in a controllable system, with higher yields and better quality.